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Abstract
Background: The purpose of this study was to evaluate the activity of Selective Inhibitors of Nuclear Export (SINE)
compounds that inhibit the function of the nuclear export protein Exportin 1 (XPO1/CRM1) against canine tumor cell lines
and perform a Phase I clinical trial of KPT-335 in dogs with spontaneous cancer to provide a preliminary assessment of
biologic activity and tolerability.
Methods and Findings: Canine tumor cell lines derived from non-Hodgkin lymphoma (NHL), mast cell tumor, melanoma
and osteosarcoma exhibited growth inhibition and apoptosis in response to nanomolar concentrations of SINE compounds;
NHL cells were particularly sensitive with IC50 concentrations ranging from 2–42 nM. A Phase I clinical trial of KPT-335 was
performed in 17 dogs with NHL (naive or relapsed), mast cell tumor or osteosarcoma. The maximum tolerated dose was
1.75 mg/kg given orally twice/week (Monday/Thursday) although biologic activity was observed at 1 mg/kg. Clinical benefit
(CB) including partial response to therapy (PR, n = 2) and stable disease (SD, n = 7) was observed in 9/14 dogs with NHL with
a median time to progression (TTP) for responders of 66 days (range 35–256 days). A dose expansion study was performed
in 6 dogs with NHL given 1.5 mg/kg KPT-335 Monday/Wednesday/Friday; CB was observed in 4/6 dogs with a median TTP
for responders of 83 days (range 35–354 days). Toxicities were primarily gastrointestinal consisting of anorexia, weight loss,
vomiting and diarrhea and were manageable with supportive care, dose modulation and administration of low dose
prednisone; hepatotoxicity, anorexia and weight loss were the dose limiting toxicities.
Conclusions: This study provides evidence that the novel orally bioavailable XPO1 inhibitor KPT-335 is safe and exhibits
activity in a relevant, spontaneous large animal model of cancer. Data from this study provides critical new information that
lays the groundwork for evaluation of SINE compounds in human cancer.
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Introduction
The exchange of proteins between the nucleus and cytoplasm is
a tightly regulated process that involves several proteins respon-
sible for shuttling cargo in and out of the nucleus. There are seven
known nuclear export proteins (Exportin 1–7) that carry macro-
molecules from the nucleus to the cytoplasm [1,2,3]. Exportin 1
(XPO1, also called Chromosome Region Maintenance protein 1
[CRM1]) is a member of the karyopherin b family of transport
receptors that binds a very diverse set of approximately 220 target
proteins through a hydrophobic leucine-rich nuclear export signal
(NES) present in the cargo [4]. Interaction of the NES-directed
protein cargo with the small GTPase molecule Ran leads to
cytoplasmic transport via a nuclear pore complex [5]. XPO1 is the
sole nuclear exporter of several major tumor suppressor and
growth regulatory proteins (TSPs and GRPs, including p53, p75,
Rb, p21, p27, STAT3, FOXO and IkB among others) [6,7].
Expression of XPO1 is known to be upregulated in a variety of
both hematologic malignancies and solid tumors and this
correlates with a poor prognosis [1,2,3], indicating that changes
in nuclear-cytoplasmic trafficking resulting in aberrant localization
of key proteins can contribute to tumorigenesis and potentially
resistance to therapy.
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Several small molecule inhibitors of XPO1 have been developed
and tested against a variety of neoplastic cells, primarily in vitro.
These include Leptomycin B, ratjadone, anguinomycin, goniotha-
lamin, among others, that bind covalently to a reactive cysteine
residue (Cys528) located in the NES-binding groove of XPO1
[1,2,3]. This binding functionally inactivates XPO1 in an
irreversible manner and targets the protein for proteasome
degradation [8], resulting in restoration of TSP and GRP cellular
localization and function. For example, Leptomycin B causes
nuclear retention of the BCR-ABL1 fusion protein and induces
apoptosis when co-administered with imatinib to CML cells in vitro
[9]. While Leptomycin B exhibits activity against several cancer
cell lines in vitro and mouse xenograft tumor models, it induces
significant systemic toxicity in both animals and humans resulting
in discontinuation of clinical development [10]. More recently,
analogs of Leptomycin B have been developed that demonstrate
greater potency in vitro and in vivo with a significantly reduced
toxicity profile in mice [11]. However, these agents require
intravenous delivery, limiting the frequency of drug administra-
tion.
Recently, novel, drug-like, orally bioavailable, small-molecule
Selective Inhibitor of Nuclear Export (SINE) compounds that
specifically and irreversibly bind to XPO1 at the reactive site Cys
528 residue have been developed [12,13,14,15,16,17,18]. These
are slowly reversible with a t1/2 of approximately 24 hours, and
lead to functional inactivation the XPO1 protein. SINE
compounds have been shown to induce apoptosis and block
proliferation in several cancer cell lines, including those derived
from colon [6], pancreas [12], and breast carcinomas [16] as well
as chronic lymphocytic leukemia (CLL) [15], while sparing normal
cells [19]. Additional studies have shown potent anti cancer
activity and good tolerability of SINE in vivo using mouse human
xenograft (subcutaneous, orthotopic, or leukemograft) models of
pancreatic cancer [12], renal cancer [20], CLL [15], mantle cell
lymphoma (MCL) [18], multiple myeloma [8] and acute
myelogenous leukemia (AML) [17]. These data support the notion
that SINE compounds will have biologic activity in humans with
cancer.
Spontaneous canine cancers exhibit many clinical and molec-
ular similarities to human cancers and as such, serve as an
attractive model for preclinical studies that evaluate the biologic
activity and toxicities of novel anti-cancer therapeutics. Such
studies have been used to validate the activity of multi-targeted
receptor tyrosine kinase inhibitors (toceranib) [21,22], new
chemotherapeutic agents (GS-9219) [23], and various other small
molecule inhibitors (ibrutinib, STA-1474) [24,25]. Therefore, the
purpose of this work was to examine the effects of SINE
compounds in canine spontaneous cancers. Specifically, their
activity was first assessed in vitro against canine tumor cell lines
with a specific emphasis on hematopoietic tumors, after which a
Phase I study of the novel SINE KPT-335 was performed in dogs
with metastatic osteosarcoma, mast cell tumor and non-Hodgkin
lymphoma (NHL). These studies laid the groundwork for the
current Phase I evaluation of the SINE compound KPT-330 in
humans with cancer and for a potentially pivotal study of KPT-
335 for dogs with newly diagnosed or relapsed NHL.
Materials and Methods
Primary Tumor Samples and Cell Culture
Cryopreserved tumor cells obtained from sterile lymph node
biopsy samples from dogs with diffuse large B cell lymphoma
(DLBCL) were cultured with 100 ng/mL of megaCD40L (Enzo
Life Science, Plymouth Meeting, PA) as previously described
[26,27]. The human T-cell leukemia cell line, Jurkat, was from the
American Type Culture Collection (ATCC, Manassas, VA) and
cultured in RPMI1640 medium (Gibco/BRL, Grand Island, NY)
containing 10% fetal bovine serum (FBS; Atlas Biologicals, Fort
Collins, CO), 2-mercaptoethanol (Gibco/BRL), HEPES, L-
glutamine, sodium pyruvate (Mediatech Inc., Manassas, VA),
non-essential amino acids (Sigma Aldrich, St. Louis, MO), and
Primocin (Invivogen, San Diego, CA). The canine DLBCL cell
line CLBL1 obtained from Dr. Barbara Ru¨tgen (University of
Vienna, Austria) [28,29] and human DLBCL cell lines OCI-Ly3
[30,31] and OCI-Ly10 [32] obtained from Dr. Anne Novak
(Mayo Clinic Cancer Center, Rochester, MN) were cultured in
complete Iscove’s Modified Dulbecco’s medium (IMDM) contain-
ing 20% FBS, L-glutamine, and Primocin. All cells were
maintained at 37uC in a humidified 5% CO2 atmosphere. The
following additional canine tumor cell lines were used to evaluate
response to SINE compounds: C2, mast cell tumor line provided
by Dr. George Caughey, UCSF, San Francisco, CA [33]; OSA16,
osteosarcoma cell line, provided by Dr. Jaime Modiano, UM,
Minneapolis, MN [34]; and 323610-3, malignant melanoma cell
line, provided by Dr. Michael Kent, UCD, Davis, CA [35]. All cell
lines were cultured in complete RPMI media containing 10%
FBS, antibiotic/antimycotic, HEPES, sodium pyruvate, nonessen-
tial amino acids and Glutamax (media supplements from Gibco).
Viability and Proliferation Assays
Cell viability for lymphoid lines was determined by the MTS (3-
(4, 5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfo-
phenyl)-2H-tetrazolium) assay using CellTiter 96H AQueous One
Solution Cell Proliferation Assay Kit (Promega, Madison, WI).
Briefly, for lymphoid cell lines, 56104 cells (or 16105 primary
DLBCL cells) were cultured in 100 mL of complete medium in 96-
well plates in the presence of SINE compounds. After 72 hours,
20 mL of MTS solution was added to each well and cells were
incubated for another 4 hours before measuring absorbance at
490 nm using a Wallac Victor 1420 Multilabel Counter (Perkin
Elmer, Waltham, MA). The IC50 of SINE was calculated using
Prism 6 software (GraphPad Software, Inc., La Jolla, CA).
For the non-lymphoid cell lines, 96 well plates were seeded in
triplicate in 90 mL with 2500 cells/well of OSA16, 5000 cells/well
of C2, and 2500 cells/well of 323610-3. Seeded plates were
cultured overnight then treated the following day with 10 mL of
KPT-214 in C10 media at concentrations of 0.0001, 0.01, 0.1, 1.0,
and 10 mM. Plates were collected at 92 hours, centrifuged at
1300 rpm, and supernatant was removed by inverting plates on
absorbent paper. Plates were then sealed and immediately placed
at 280uC for a minimum of 12 hours. Plates were then thawed
and CyQUANT HCell Proliferation Assay (Life Technologies) was
performed following the manufacturer’s protocol. Briefly, 200 mL
of the diluted working CyQUANT solution was added to each well
and protected from light. Fluorescence was the measured using a
SpectraMax M2 microplate reader at 480 nm excitation and
520 nm emission. Results were represented as percent of control,
or plotted to calculate IC50 values at 92 hours.
Apoptosis Assay
Jurkat cells and primary canine DLBCL cells were cultured for
24 hours in the presence of 100 nM KPT-335 or dimethyl
sulfoxide (DMSO). Cells were stained with Annexin V (eBios-
ciences, San Diego, CA) according to the manufacturer’s
instruction. Flow cytometry was performed using a BD LSRII
flow cytometer (BD Immunocytometry Systems, San Jose, CA)
and results were analyzed using FlowJo software (Tree Star,
Ashland, OR).
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Immunoblotting
Cryopreserved primary canine DLBCL and CLBL1 cells were
lysed in RIPA buffer containing 150 mM NaCl, 50 mM Tris,
pH 7.4, 0.1% sodium dodecyl sulfate (SDS), 1.0% Triton X-100,
1.0% sodium deoxycholate, 5 mM EDTA, 1 mM dithiothreitol,
and a Proteinase Inhibitor Cocktail (Sigma-Aldrich, St. Louis,
MO). Insoluble material was removed by centrifugation, and
protein concentrations of the cell lysates were determined using
the BioRad Protein Assay kit (BioRad, Hercules, CA). Proteins
(100 mg) were separated by SDS-polyacrylamide gel electropho-
resis (SDS-PAGE) and transferred to nitrocellulose membranes
(BioRad, Hercules, CA). Antibody staining was performed using
the SNAP i.d. system (EMDMillipore, Billerica, MA) according to
the manufacturer’s instructions. Briefly, membrane was blocked by
50% LI-COR blocking buffer (LI-COR, Lincoln, NE) and stained
with rabbit anti-XPO1 antibody (1:66 dilution, Santa Cruz, Santa
Cruz, CA) and mouse anti-actin antibody (1:1666 dilution, Sigma-
Aldrich), followed by secondary donkey anti-rabbit antibody
conjugated to IRDye800 and anti-mouse antibody conjugated to
IRDye680 (1:3,333 dilution, LI-COR). Detection was performed
using the Odyssey Infrared Imaging System (LI-COR).
KPT-335 Formulation
KPT-335 was prepared as gelatin filled capsules in strengths
ranging from 2.5 mg to 20 mg of active pharmaceutical ingredient
(API). The API was wet milled with Lutrol F68 NF (BASF) and
water in a Microfluidics micro-fluidizer, combined with Plasdone
K29/30 (ISP Technologies), and lyophilized. Lyophilized powders
contained 70–75% API. Capsules were individually hand filled
with lyophilized powder to the desired dosage strength. All
excipients were of suitable grades for use in pharmaceuticals.
Pharmacokinetic Analysis in Healthy Dogs
KPT-335 was administered as a single oral dose in capsule
formulation to 6 male beagle dogs at approximately 1.5 mg/kg
following a meal. Serial blood samples were collected from each
dog prior to dosing and at 0.25, 0.5, 1, 2, 4, 6, 8, 12, 18, 24 and 48
hours post-dose and placed into tubes containing K2EDTA. Blood
samples were stored on wet ice until processed to plasma by
centrifugation at 3500 rpm for 10 minutes at 5uC. Plasma samples
were stored in at 280uC until analysis at Agilux Laboratories
(Worcester, MA). Plasma samples were analyzed for parent drug
concentration using sample preparation by protein precipitation
and then analysis by LC-MS/MS using propranolol as the internal
standard. The method was qualified for use (a single batch to
assess method performance: precision and accuracy; linearity of
dilution; and matrix specificity) prior to initiation of sample
analysis. Acceptance criteria for calibration standards and quality
control samples were within 630% nominal concentration.
Individual animal pharmacokinetic parameter values were derived
by the pharmacokinetic analysis program Phoenix WinNonlin
version 6.3 (Pharsight Corporation), using the non-compartmental
Model 200 with uniform weighting. The single-dose pharmaco-
kinetic parameters assessed include: Cmax (maximum concentra-
tion observed); Tmax (time of observed maximum concentration);
AUC0R‘ (area under the concentration-time curve from time zero
extrapolated to infinity); AUC0Rlast (area under the concentration-
time curve from time zero to the time of the last quantifiable
concentration); and t1/2 (terminal half life). Descriptive statistical
data (mean, standard deviation, and standard error of the mean)
were calculated from the unrounded numbers in an Excel
(Microsoft) spreadsheet. Concentration results, means, and calcu-
lated parameters were reported to 3 significant figures.
Clinical Trial Eligibility
This clinical trial was approved by the Ohio State University
(OSU) Veterinary Medical Center (VMC) Clinical Research
Advisory Committee and the OSU IACUC; IACUC approval was
also obtained at University of Minnesota and Texas A&M
University. Written informed consent from the owner of each
dog was obtained prior to study entry. KPT-335 was administered
to dogs with metastatic osteosarcoma, mast cell tumor or NHL
that had failed conventional therapy or for which there were no
therapeutic alternatives, or for which conventional therapy was
not desired by the owner. To be eligible for the study, each dog
must have been definitely diagnosed via cytology or histopathology
and had met all of the inclusion criteria and none of the exclusion
criteria. Additional eligibility criteria included: .1 year old at
study entry; adequate organ function; at least 2 weeks since prior
chemotherapy or radiation with complete recovery from the acute
toxicities of these treatments (3 weeks for a surgical procedure); at
least 1 week since prior treatment with any other investigational
drug; and no evidence of brain metastases or any serious systemic
disorder incompatible with the study at the discretion of the
investigator.
Study Design
This study was a Phase I dose escalating, open label assessment
of the safety and biologic activity of KPT-335 in client owned dogs
with spontaneous malignancies. Assessment of clinical toxicities
and tumor response was performed at each visit. Dogs were
evaluated for hematologic and biochemical toxicities every 7 days
with routine bloodwork. The initial dose of 1 mg/kg orally twice
per week (Monday/Thursday or Tuesday/Friday) was based on
previous data from normal laboratory dogs (data not shown) and
dose escalation was set at 0.25 mg/kg increments in cohorts of 3
until dose limiting toxicity (DLT) was identified. The DLT was
considered to be any grade 3 or 4 hematologic or non-hematologic
toxicity based on the established VCOG-CTCAE criteria [36].
Additionally, any chronic non-grade 3 or 4 toxicities considered to
significantly impair quality of life (i.e., lethargy, inappetence) were
qualified as DLTs. Disease progression or signs and symptoms
definitely related to disease were not considered adverse events
(AEs). The maximum tolerated dose (MTD) was considered to be
one dose below that at which DLT occurred.
Toxicity Assessment
Each patient underwent a baseline complete history, physical
examination, and pre-dose laboratory assessment that included a
complete blood count (CBC), serum biochemistry profile, coagu-
lation parameters (PT/PTT) and urinalysis. Patients were assessed
for adverse events on days 7, 14, 21, and 28, and every 2 weeks
thereafter at which time all laboratory assessments were repeated.
Stipulations regarding minimal hematological requirements to
continue dosing were included in the protocol: hematocrit .25%,
neutrophils .1500/L, platelets .100,000/L. In addition, liver
transaminases were required to be ,4X upper limit of normal
with a normal total bilirubin and serum creatinine to continue
KPT-335 therapy.
Concomitant Medications
To treat drug-related gastrointestinal toxicities, supportive care
was administered as needed to dogs enrolled in this study. This
typically consisted of famotidine, omeprazole, metronidazole,
loperamide, metoclopramide, ondansetron, and/or maropitant.
Antihistamines were administered to dogs with mast cell tumors,
as these tumors are known to release histamine. Other supportive
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care administered to dogs consisted of prednisone and non-
steroidal anti-inflammatory medications to treat tumor-associated
inflammation, inappetence, and for pain control.
Tumor Response Assessment
Tumor assessments were completed prior to study entry, and
days 7, 14, 21, and 28. For dogs that continued beyond 4 weeks,
response assessments were performed every 2 weeks thereafter, or
at the time of suspected tumor progression. Responses were
assessed by the investigator according to pre-defined protocol
criteria. The response in dogs with assessable disease was
performed by clinical examination, ultrasonography, or thoracic
radiography. Many lesions were not amenable for quantitative
radiographic imaging, but were followed either by serial clinical
examination (superficial lesions; palpable lymph nodes) or by
ultrasonography (abdominal lymph nodes). Thoracic lesions were
assessed by thoracic radiography.
The response in dogs with measurable disease was judged by the
investigator on the basis of Response Evaluation Criteria for
Peripheral Nodal Lymphoma in dogs (v1.0) [37]. A complete
response (CR) was defined as disappearance of all disease on two
measurements separated by a minimum period of 3 weeks. A
partial response (PR) was defined as greater than 30% reduction in
the sum of the longest diameter of the target lesions documented
by two assessments separated by at least 3 weeks. An increase of
.20% in the size of all measurable tumor areas as measured by
the sum of longest diameters of the target lesions taken as reference
the smallest sum since initiation of therapy, or the appearance of
any new lesion(s) would qualify as progressive disease (PD). Stable
disease (SD) was defined by the absence of criteria for either a
response or progression; to be considered SD, dogs must have
demonstrated no evidence of PD at the 28 day assessment. Dogs
who had no evidence of tumor progression and who had not
experienced any unacceptable toxicity were eligible for extended
treatment cycles. Dose escalation from twice per week adminis-
tration to three times per week administration in an individual dog
was permitted if the dog was tolerating therapy.
Quality of Life Assessment
A tool to assess quality of life in dogs with cancer during
treatment has been previously published [38]. This was used to
assess owner perceived changes in dogs undergoing KPT-335
treatment during both the dose escalation and dose expansion
studies. An overall quality of life (QOL) score was created based on
answers to the questions on the quality of life questionnaire. The
scores from each question were summed resulting in an overall
quality of life score which could range from 23 to 115. Trends in
Quality of Life (QOL) during the study were examined using
linear mixed models containing fixed effects of time and an
autoregressive correlation structure for the random errors. Wald
tests were used to test for a significant change in QOL with
degrees of freedom calculated using the Kenward-Roger method
[39]. Measurements obtained after 90 days were not included in
the analysis for the dose escalation study and measurements after
70 days were not included in the analysis of the dose expansion
data due to few data points after those time points.
Results
Activity of SINE Compounds against Canine Tumor Cells
in vitro
We first evaluated the effect of KPT-185, which is one of the
most potent SINE compounds but with limited oral bioavailability
and therefore only suitable for the in vitro studies, on Jurkat
(human T cell leukemia) cells and 6 primary canine DLBCL
samples (5 distinct tumors with one pair of the same tumor). KPT-
185 effectively inhibited the viability of Jurkat and canine DLBCL
cells (Figure 1A and Table 1). The IC50 of KPT-185 against Jurkat
(n = 3) and primary canine DLBCL samples (n = 6) were
8.760.7 nM and 13.366.2 nM, respectively. KPT185-trans
isomer (which has ,100 fold less XPO1 inhibition activity as
the cis-isomer), showed much less toxicity when it was tested using
Jurkat cells and one of primary canine DLBCL samples (IC50 were
.1000 nM in both tumor cells). Next, we evaluated the effect of
KPT-335, a clinical candidate compound with good oral exposure
used in this clinical trial, on canine and human DLBCL cells.
KPT-335 inhibited the viability of OCI-Ly3, OCI-Ly10, and
CLBL1 at the IC50 of 2.161.3 nM, 41.8621.0 nM, and
8.564.1 nM, respectively (Figure 1B and Table 1). We also
demonstrated KPT-335 induced apoptosis in CLBL1 cells and
primary canine DLBCL cells using flow cytometry. Treatment of
cells with KPT-335 for 24 hours increased apoptotic cells (Annexin
V+ cells) compared to mock treated cells (Figure 1C). Finally, we
confirmed the expression of XPO1, which was detected by the
estimated size of XPO1 (,123 kDa), in dog cells using the CLBL1
cell line, human DLBCL cell lines, and canine primary DLBCL
cells (Figure 1D). Taken together, both human and canine
DLBCL express XPO1 and SINE compounds show potent
activity against these tumor cells, suggesting a potential therapeutic
benefit for human and canine patients with DLBCL.
To provide a preliminary assessment of the potential activity of
SINE XPO1 antagonists against additional canine cancers, the C2
mast cell tumor line, the OSA16 osteosarcoma cell line, and the
323610-3 melanoma cell line were utilized. For these studies an
earlier analog, KPT-214, was available for the in vitro experi-
ments (Figure 2). The IC50 of KPT-214 against the C2, OSA16
and 323610 were 490 nM, 89 nM, and 70 nM, respectively. In
summary, the SINE exhibit biologic activity in vitro against a wide
variety of canine tumor cell lines, with lymphoid lines being the
most sensitive in the very low nanomolar range. These data
supported the subsequent in vivo evaluation of SINE in dogs with
spontaneous cancers, with a particular emphasis on dogs NHL.
Pharmacokinetics of KPT-335 in Healthy Dogs
To assess the pharmacokinetics of KPT-335, six healthy beagle
dogs were administered a single dose of drug at 1.5 mg/kg after
being fed a meal. Blood samples were obtained over a 48 hour
time period and analyzed for plasma KPT-335 concentrations.
The results are shown in Table 2. The mean Tmax was
approximately 4 hours with a Cmax of approximately 250 ng/
ml, and an average AUC of 1800 ng/ml.
Dose Escalation Study
Patient demographics. Patient demographics and tumor
types are listed in Table 3. A total of 17 dogs were enrolled into the
dose escalation portion of the study. The median age was 7.5 years
and the median weight was 35 kg. The majority of dogs enrolled
had NHL (n= 14), and most (n = 12) had also received prior
therapy including surgery, chemotherapy and/or prednisone.
Prednisone was administered to 10 dogs during the course of
KPT-335 treatment at 0.5 mg/kg either once per day or every
other day; in 8/10 cases, the dogs entered the study after having
experienced disease progression in the face of prednisone therapy
and consequently, the drug was not discontinued. The remaining
two dogs were placed on prednisone after the first 28 days of
treatment to address inappetence/anorexia associated with
treatment. These dogs received prednisone at 0.5 mg/kg every
other day for the duration of treatment with KPT-335.
SINE KPT-335 in Spontaneous Canine Cancer
PLOS ONE | www.plosone.org 4 February 2014 | Volume 9 | Issue 2 | e87585
Clinical toxicities and maximum tolerated dose. For all
dogs enrolled in the dose escalation portion of the study, the
primary clinical toxicities consisted of mainly grade 1 and 2
gastrointestinal events including anorexia, vomiting and diarrhea,
as well as lethargy (summarized in Tables 4 and 5). The MTD was
established as 1.75 mg/kg given twice per week (Monday/
Thursday). All three dogs in the 2 mg/kg cohort experienced
DLT including grade 3 anorexia (n = 2), grade 3 vomiting (n = 1),
grade 3 diarrhea (n= 1), grade 3 ALT elevation (n = 2), grade 3
AST elevation (n= 1), and grade 3 ALP elevation (n= 1).
Therefore, the adverse event profile of KPT-335 was mainly
limited to the gastrointestinal tract and clinically relevant
hepatotoxicity was observed mainly at doses above the MTD.
In 4 cases, dogs that were on drug for over 4 weeks had a
change in regimen from twice per week to three times per week
(Monday/Wednesday/Friday) as drug was well tolerated and the
dogs were experiencing stable disease. This occurred in one dog
receiving 1 mg/kg, two dogs receiving 1.25 mg/kg, and one dog
receiving 1.5 mg/kg. They remained on this increased dosing
frequency regimen for the duration of therapy (median 68.5 days)
without any increase in clinical toxicities. In 4 cases dose
modifications were made for dogs that experienced adverse
events. Two of these occurred in dogs that received drug at
2 mg/kg and experienced grade 3 adverse events; in both
instances, the dose was reduced to 1.5 mg/kg twice per week. In
the other two instances, one dog was reduced from 1.75 mg/kg to
1.5 mg/kg then 1.25 mg/kg due to continuing issues with
anorexia, and the other dog was reduced from 1.5 mg/kg to
Figure 1. Biologic activity of SINE compounds against canine NHL cells. (A) Jurkat cells and primary canine DLBCL cells (sample #1–5, #5
was independently tested twice) were cultured in 96-well plates for 72 hours with log serial dilutions of KPT-185 and the cell viability was analyzed
using the MTS assay. Each experiment was performed in duplicate wells and experiments were repeated three times (B) Human and canine DLBCL
cells were cultured in a 96-well plate for 72 hours with 3-fold serial dilutions (0–1000 nM) of KPT-335 and analyzed using the MTS assay. Each
experiment was performed in duplicate wells and experiments were repeated three times. (C) CLBL1 cells and primary canine DLBCL cells (sample
#1) were treated with 100 nM KPT-335 for 24 hours and analyzed for apoptosis using flow cytometry. Experiments were performed three times
independently and the average results are shown. (D) Expression of XPO1 in human and canine DLBCL cell lines. Protein lysates prepared from OCI-
Ly3, OCI-Ly10, and CLBL1 were separated by SDS-PAGE and subjected to immunoblotting for XPO1; b-actin served as the control.
doi:10.1371/journal.pone.0087585.g001
Table 1. IC50 (6 S.D.) of SINE for human and canine
lymphoma cells.
KPT-335 KPT-185 KPT-185 trans
Jurkat 0.3 8.760.7 .1000
OCI-Ly3 2.161.3 24.1 NP
OCI-Ly10 41.8621.0 246.2 NP
CLBL1 8.564.1 NP NP
Canine DLBCLs – 13.366.2 –
DLBCL#1 2.0 13.1 NP
DLBCL#2 NP 9.0 NP
DLBCL#3 NP 12.2 NP
DLBCL#4 NP 4.9 NP
DLBCL#5 NP 21.6 .1000
IC50, 50% inhibitory concentration; DLBCL, diffuse large B-cell lymphoma;
NP, not performed.
doi:10.1371/journal.pone.0087585.t001
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1.25 mg/kg, also due to anorexia. This last patient remained on
therapy for 246 days.
Response to therapy. The median TTP for all dogs was 35
days (range 14–246 days). A total of 7 dogs experienced PD in the
first 4 weeks of therapy. Two dogs had a PR for 71 and 246 days,
and 8 dogs experienced SD for a median of 58.5 days (range 28–
84 days). Of these 10 dogs, 6 were receiving prednisone prior to
starting KPT-335 that continued during treatment and 4 did not
Figure 2. Biologic activity of SINE compounds against canine tumor cell lines. Canine tumor cell lines C2 (mast cell), OSA16 (osteosarcoma)
and 323610-3 were cultured in 96 well plates in triplicate with serial dilutions of KPT-214 for 92 hours after which the plates were collected, media
removed, and the plates were frozen at 280uC. Analysis for effects on cell proliferation was then performed using the CyQUANT assay according to
the manufacturer’s specifications. Experiments were repeated three times; the IC50 for each cell line is shown.
doi:10.1371/journal.pone.0087585.g002
Table 2. Pharmacokinetics of KPT-335 in healthy dogs.
Parameter KPT-335 at 1.5 mg/kg
Dose (mg/kg)
Mean 1.46
SD 0.0542
SEM 0.0221
Cmax (ng/mL)
Mean 253
SD 88.3
SEM 36.1
Tmax (hr)
Mean 3.83
SD 2.71
SEM 1.11
t1/2 (hr)
Mean 3.88
SD 1.47
SEM 0.602
AUC0-‘ (h*ng/mL)
Mean 1810
SD 216
SEM 88.2
AUC0-last (h*ng/mL)
Mean 1760
SD 223
SEM 90.9
doi:10.1371/journal.pone.0087585.t002
Table 3. Subject demographics.
Characteristics Dose Escalation Dose Expansion
Number of dogs 17 6
Age (yrs)
Median 7.5 6.75
Mean 7.7 6.4
Range 4–11 4.5–8
Weight (kgs)
Median 32 23.95
Mean 31.5 20.83
Range 6.2–66.7 4.5–31.4
Gender
Male intact 1 0
Male neutered 8 3
Female intact 1 0
Female neutered 7 3
Tumor Type
Lymphoma 14 6
Mast cell tumor 2 N/A
Osteosarcoma 1 N/A
Prior Treatment
Yes 5 4
No 12 2
Prednisone
Yes 10 6
No 7 0
doi:10.1371/journal.pone.0087585.t003
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receive prednisone during their treatment. All but one of the dogs
with clinical benefit (CB) associated with KPT-335 administration
(PR or SD.4 weeks) had NHL with a median TTP in responding
dogs of 66 days (range 35–256 days).
Dose Expansion Study
Patient demographics. Based on the results of the dose
escalation study and responses to therapy observed in dogs with
NHL, an additional 6 dogs with NHL received KPT-335 at
1.5 mg/kg given on a Monday/Wednesday/Friday schedule.
Patient demographics are again provided in Table 3. The median
age was 6.75 years and the median weight was 23.95 kg. Four of
the dogs had previously received treatment for their NHL
(primarily multi-agent chemotherapy), and all were receiving
prednisone as part of their therapy, with demonstrated progression
of disease prior to study entry. These dogs were maintained on
prednisone at 0.5 mg/kg either daily or every other day during
KPT-335 administration. Two other dogs had not received any
prior therapy and prednisone at 0.5 mg/kg given every other day
was administered to alleviate anorexia/inappetence after 28 days
on study for the duration of KPT-335 treatment.
Clinical toxicities. As with the dose escalation portion of the
study, the most common toxicities were gastrointestinal in nature
and primarily grade 1 and 2 in severity, including anorexia, weight
loss, vomiting and diarrhea (summarized in Tables 4 and 5). The
grade 3 adverse events consisted of anorexia (n = 1), increased
ALT (n= 1, not clinically relevant), and increased ALP (n= 2,
most likely related to ongoing prednisone administration); one dog
had a grade 4 ALP elevation, again most likely related to
prednisone therapy.
Response to therapy. The median TTP for all dogs was 55
days (range 13–354 days). Two dogs had a PR for 35 and 354
days, and 4 dogs experience SD for longer than 28 days, for a CB
rate of 67% (4/6 dogs) with a median TTP of 83 days (range 35–
354 days).
Quality of Life Assessment
Dog owners were asked to complete a health related Quality of
Life (QOL) form prior to study entry and at each recheck visit
[38]. As shown in Figure 3, the overall quality of life did not
change significantly in dogs treated in either the dose escalation
study (p= 0.64) or dose expansion study (p= 0.47). These data
support the notion that clinical toxicities associated with KPT-335
did not decrease quality of life in treated dogs.
Discussion
XPO1 is responsible for the nuclear-cytoplasmic export of over
200 proteins [4,40] and several RNAs, many of which mediate
pathways that control proliferation and survival. Several studies
have now demonstrated that adequate function of XPO1 is
necessary for cancer cells to survive [2,3]. Interestingly, XPO1
inhibition appears to have selective effects primarily on cancer
cells, while sparing normal cells in most cases [19]. The
mechanisms responsible for this differential effect are not entirely
clear. The majority of tumor suppressor proteins (TSPs) such
including p53, p73, p21, p27, Rb and FOXO are exported from
the nucleus exclusively by XPO1 [7,41]. Inhibition of XPO1
results in forced nuclear retention, upregulation, and activation of
TSPs [1,2,3]. Restoration of TSP function can induce apoptosis in
cells with a damaged genome, including tumor cells. Since XPO1
inhibition leads to the restoration of so many TSPs at once, it is
theorized that anti-tumor activity can be independent of
oncogenic drivers responsible for maintenance of the neoplastic
Table 4. Constitutional and gastrointestinal toxicities.
Dose (mg/kg) No. of dogs Lethargy Anorexia Weight Loss Vomiting Diarrhea
1 2 3 4 1 2 3 4 1 2 3 4 1 2 3 4 1 2 3 4
1.0 3 1 2 1 3 1 1
1.25 3 2 3 1 2 1
1.5 5 3 1 3 2 5 2 2 1 1
1.75 3 2 1 1 1 2 2 1 1 1
2.0 3 1 1 2 3 2 1 2 1 1
1.5 MWF 6 3 7 1 1 4 2 3 1 3 1
doi:10.1371/journal.pone.0087585.t004
Table 5. Hepatic and hematologic toxicities.
Dose (mg/kg) No. of dogs ALP ALT Bilirubin Anemia Thrombo-cytopenia
1 2 3 4 1 2 3 4 1 2 3 4 1 2 3 4 1 2 3 4
1.0 3 4 2 1 2 1 2 1
1.25 3 1 2 3 1 1
1.5 5 4 1 3 1 1 3 2 3
1.75 3 1 1 1 1 1 1 1
2.0 3 2 1 1 2 1 2 1 1 2
1.5 MWF 6 2 1 1 4 2 1 1 1 1 1
doi:10.1371/journal.pone.0087585.t005
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phenotype [42,43]. It has also been suggested that when TSPs
localize to the nucleus, a genome survey is initiated that tumor
cells fail. In contrast, XPO1 inhibition in normal cells typically
results in a transient cell cycle arrest in the absence of cell death
and subsequent recovery once inhibition has been relieved. This
phenomenon was demonstrated in vitro where inhibition of XPO1
did not induce cytotoxicity in normal B, T and NK cells [15,19].
While several small molecule inhibitors of XPO1 have been
previously developed, only a few have been tested in mouse
models. Despite its marked toxicities in animals, the natural
product Leptomycin B is the sole XPO1 inhibitor that was tested
in human clinical trials prior to the development of the SINE
compounds. Consistent with side effects identified in mice, a Phase
I study in people induced severe anorexia and malaise while
providing no evidence of biologic activity prohibiting its further
clinical development [10]. The semi-synthetic Leptomycin B
derivative KOS-2464 with improved pharmacological parameters
compared with Leptomycin B, exhibited significant activity against
several tumor cell lines in vitro, while sparing normal cells. KOS-
2464 given intravenously was active in all mouse xenograft models
tested while inducing significantly less weight loss than Leptomycin
B [11]. An oral small molecule reversible inhibitor of XPO1,
CBS9106 induced cell cycle arrest and apoptosis in 60 different
human tumor cell lines and suppressed tumor growth in mouse
xenografts without any significant morbidity or mortality [44].
Both KOS-2464 and CBS9106 have not yet been evaluated in
human clinical trials.
SINE compounds are a series of orally bioavailable, slowly
reversible inhibitors of XPO1 that demonstrate high specificity for
target, based on covalent binding to the reactive cysteine 528
residue in the cargo binding domain [12,15,17,19]. Several of the
early analogs have been evaluated in vitro and in mouse models of
cancer and all have shown excellent biologic activity with minimal
toxicity. KPT-185 and KPT-276 were shown to be active against
AML cell lines and primary blasts from patients, and significantly
prolonged the survival of leukemic mice in a FLT3-ITD+ AML
xenograft model [14,17]. Similar results were obtained with KPT-
251 in a CLL mouse model [15]. Activity of KPT-185 and KPT-
276 was demonstrated against MCL, follicular lymphoma and
DLBCL both in vitro and in mouse models of disease [18,45].
Inhibition of XPO1 using KPT-185, -251, -276, and -330
impaired melanoma survival in both BRAF mutant and wild-type
melanoma cell lines and in mouse xenografts [46]. Furthermore,
SINE compounds exhibited synergistic activity with BRAF
inhibitors PLX4720 and PLX4032 against BRAF mutant mela-
noma [46]. Lastly, several of the SINE compounds including
KPT-330 have shown activity against pancreatic cell tumor lines
in vitro and slowed tumor growth of subcutaneous and orthotopic
xenograft tumors [12]. Importantly, all of the compounds tested
exhibited a good safety profile in the mouse models.
Figure 3. Trends in quality of life in dogs treated with KPT-335. An overall score was created based on answers to questions on the quality of
life questionnaire. The scores from each question were summed resulting in an overall quality of life score which could range from 23 to 115. These
are represented graphically in the figure above where scores for each patient are graphed over time (each line represents a patient). Trends in quality
of life during the study were examined using linear mixed models. The overall quality of life did not change significantly in dogs treated in either the
(A) dose escalation study (p = 0.64) or (B) dose expansion study (p = 0.47).
doi:10.1371/journal.pone.0087585.g003
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The purpose of the current study was first to evaluate the effect
of SINE compounds in canine tumor cell lines, and then second, to
assess KPT-335 in a spontaneous model of cancer that would
provide important information regarding dose, regimen, and
clinical toxicity profile thereby laying the groundwork for
subsequent human clinical trials. Our data demonstrate that
similar to the case of human cancer cell lines, KPT-185, KPT-214
and the clinical candidate KPT-335 all demonstrate inhibition of
cell proliferation and induction of apoptosis in multiple canine
tumor cell lines, with particularly strong activity against canine
NHL cells. This was anticipated as the sequence (Cys528
equivalent) and binding pockets of XPO1 from Schizosacchar-
omyces pombe up to humans are highly conserved [1,2,3]. In
canine NHL lines, biologic effects were noted in the low
nanomolar range with IC50 concentrations typically below
20 nM. This is concordant with the effects of other SINE
compounds against human AML, MCL and CLL cell lines.
Additionally, we found that KPT-214 was active against canine
mast cell tumor, osteosarcoma, and melanoma cell lines, also at
nanomolar drug concentrations; studies are ongoing to evaluate
the biologic activity of KPT-335 against canine melanoma cell
lines and inhibition of cell proliferation and viability has been
observed at IC50 concentrations ranging from 95–290 nM (data
not shown). Based on these data and information generated from
evaluation of KPT-335 administration to normal dogs, a Phase I
study was initiated in dogs with spontaneous cancers including
NHL, mast cell cancer, metastatic osteosarcoma and malignant
melanoma.
For the clinical trial in dogs with cancer, KPT-335 was used as
this compound exhibits excellent oral bioavailability and good
pharmacokinetic properties in normal laboratory dogs. In this
setting, doses below 3 mg/kg given either twice per week or three
times per week (Monday/Thursday or Monday/Wednesday/
Friday) were found to be tolerable, with 2 mg/kg considered to be
the MTD for chronic administration (data not shown). Given this
information, KPT-335 dosing for the Phase I study was initiated at
1 mg/kg Monday/Thursday. DLT were observed at 2 mg/kg and
as such the maximum tolerated dose was established as 1.75 mg/
kg. However, it is important to note that biologic activity was
observed at all dose levels including 1 mg/kg, with the dose of
1.25-1.5 mg/kg Monday/Thursday initially established as the
range tolerable over chronic dosing periods.
While dogs with NHL, mast cell tumor, osteosarcoma, and
melanoma were eligible to receive KPT-335 during the Phase I
dose escalation, the majority of dogs actually entered had NHL
(14/17). Within this group, 9/14 (64%) exhibited evidence of
clinical benefit (2 PR, 7 SD for greater than 28 days) following
KPT-335 administration and the median duration of treatment for
dogs with NHL was 10 weeks (range 5–35 weeks). Importantly,
biologic activity of KPT-335 was observed in dogs with NHL that
had not been previously treated as well as in dogs that relapsed or
were refractory to standard chemotherapy treatment (typically a
CHOP based regimen) and therefore were considered drug
resistant. The dose limiting toxicities observed consisted primarily
of gastrointestinal events (anorexia, weight loss, vomiting, and
diarrhea) and at 2 mg/kg, drug related hepatotoxicity (elevated
ALT, bilirubin). Although the hepatotoxicity did not result in
obvious clinical effects and rapidly resolved following drug
discontinuation, KPT-335 did induce loss of appetite that was
moderately refractory to standard anti-emetic therapy consisting of
metoclopramide, ondansetron, and/or maropitant. Inappetence
associated with minimal emesis has been observed with other
animal species, and anorexia is consistently observed across all
species, suggesting that it may be a mechanism-based toxicity.
Most of the dogs enrolled in this study had been receiving
prednisone prior to study entry and while this did appear to
enhance appetite, it did not completely resolve the toxicity in all
dogs.
The majority of dogs were dosed twice per week on a Monday/
Thursday basis, however a few dogs (n = 4) were switched to a
Monday/Wednesday/Friday regimen during ongoing therapy.
Based on these data and the observed biologic activity of KPT-335
in dogs with NHL, an expansion study was undertaken using the
three times per week regimen. We elected to use the dose of
1.5 mg/kg rather than the MTD of 1.75 mg/kg as we had
observed biologic activity at doses as low as 1 mg/kg and
anticipated having fewer challenges with anorexia and weight
loss. Clinical benefit of KPT-335 treatment occurred in 4/6 dogs
treated using this regimen, with responding dogs on drug for over
8 weeks (range 5–52). The Monday/Wednesday/Friday regimen
was associated with mainly grade 1 and 2 gastrointestinal toxicities
(anorexia, weight loss, vomiting, and diarrhea) that did not result
in drug discontinuation, although 3 dogs did undergo a dose
reduction to 1.25 mg/kg while on treatment.
As previously discussed, the primary barriers to clinical
development of previous XPO1 small molecule inhibitors have
consisted of marked anorexia and malaise observed in both mice
and humans. These toxicities have been viewed as a drug class
effect, expected to occur with all inhibitors that block XPO1
function. While anorexia was identified as one of the major dose
limiting events associated with KPT-335 administration, it was
deemed manageable when drug was administered between 1–
1.5 mg/kg on a 2 or 3 times per week basis. Indeed, several dogs
(n = 10) remained on drug for 8 weeks or longer (range 9–52)
indicating that KPT-335 is not only associated with biologic
activity in canine NHL, but can be well tolerated over chronic
administration. This is further supported by the fact that quality of
life scores, a key indicator of how dog owners perceive their dogs’
response KPT-335 therapy, did not diminish over time.
One of the limitations of this clinical trial was the potential
confounding use of prednisone in most of the dogs with NHL
treated with KPT-335 and its potential impact on response to
therapy. In both the dose escalation and dose intensification
portions of the study, approximately half of dogs with NHL were
receiving prednisone prior to study entry (11/20). For those that
experienced either PR or SD (for greater than 28 days), 7/13 had
experienced disease progression while on prednisone prior to study
entry, and the drug was not discontinued. The decision to
maintain prednisone use in these dogs was multifactorial. Several
of the dogs had been receiving drug for a long period of time and
would need to have the prednisone tapered over 2–3 weeks prior
to study entry. Additionally, given the potential issues with
anorexia, it was felt that continuing prednisone in the dogs already
being given drug might help to ameliorate this toxicity. With
respect to the remaining 6 dogs with NHL that experience CB, 4
of these were placed on low dose prednisone after 28+ days of
treatment to address anorexia. The remaining 2 dogs with CB
never received prednisone as part of their therapy. Therefore, 9/
13 dogs with CB from KPT-335 treatment either had progression
in the face of prednisone therapy or were not given prednisone
during the course of the clinical trial supporting the notion that the
observed biologic activity of KPT-335 was at least in part due to
XPO1 inhibition.
In summary, this phase I clinical trial represents the first
evaluation of a novel oral XPO1 inhibitor in a spontaneous large
animal model of cancer. Our data demonstrate that the
administration of KPT-335 results in an acceptable and tolerable
spectrum of clinical toxicities over prolonged dosing periods
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without impairment of quality of life. Furthermore, KPT-335
treatment contributed to either objective response to therapy or
prolonged disease stabilization in dogs with NHL, supporting the
notion that, as demonstrated in mouse models of disease, XPO1
inhibition has biologic activity in lymphoid malignancies. Given
the marked similarities between canine NHL and human NHL,
these data provide critical new information that has direct
applicability for the evaluation of SINE compounds in humans
with hematologic and other cancers.
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